PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity
Science Advances · 2026
DOI: 10.1126/sciadv.adu8849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Neus Martínez-Bosch und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerases, Genomic Instability, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Ministerio de Ciencia, Tecnología e Innovación Productiva, CRIS Cancer Foundation.
Abstract (Originalsprache)
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc -driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a Kras G12D -driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain.
- Cancer Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.
- Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain.
- PhD Program in Biomedicine, Facultat de Medicina (Campus Clínic), Universitat de Barcelona, Barcelona, Spain.
- Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
- Centro de Investigación Biomédica en Red Cancer (CIBERONC), Madrid, Spain.
ORCID-Profile: Neus Martínez-Bosch, Núria Vázquez-Bellón, Bennett Nickell-Hernández, Cristina Ventura-Blanch, Nura Lutfi, Carmen G Lechuga, Carlos Martínez, Mireia Moreno, Coral Ampurdanés, Etna Abad, Mar Iglesias, María Muñoz-Escribano, Ana Janic, Meritxell Rovira, Gabriel A Rabinovich, José Yélamos, Pilar Navarro
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Ciencia, Tecnología e Innovación Productiva
- CRIS Cancer Foundation
- Asociación Cáncer de Páncreas & Asociación Española de Pancreatología
- Sales and Baron Foundations
- Ramón y Cajal Research Fellowship
Zitieren
APA
Martínez-Bosch, N., Manero-Rupérez, N., Vázquez-Bellón, N., Nickell-Hernández, B., Ventura-Blanch, C., Lutfi, N., Lechuga, C. G., Martínez, C., Moreno, M., Ampurdanés, C., Abad, E., Iglesias, M., Muñoz-Escribano, M., Janic, A., Rovira, M., Guerra, C., Rabinovich, G. A., Yélamos, J., & Navarro, P. (2026). PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Science Advances. https://doi.org/10.1126/sciadv.adu8849
Vancouver
Martínez-Bosch N, Manero-Rupérez N, Vázquez-Bellón N, Nickell-Hernández B, Ventura-Blanch C, Lutfi N, et al. PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Science Advances. 2026. doi:10.1126/sciadv.adu8849
BibTeX
@article{MartnezBosch2026,
author = {Martínez-Bosch, Neus and Manero-Rupérez, Noemí and Vázquez-Bellón, Núria and Nickell-Hernández, Bennett and Ventura-Blanch, Cristina and Lutfi, Nura and Lechuga, Carmen G and Martínez, Carlos and Moreno, Mireia and Ampurdanés, Coral and Abad, Etna and Iglesias, Mar and Muñoz-Escribano, María and Janic, Ana and Rovira, Meritxell and Guerra, Carmen and Rabinovich, Gabriel A and Yélamos, José and Navarro, Pilar},
title = {PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.adu8849}
}
EUVIMED